Pre-dementia diagnosis of Alzheimer's disease: Translating clinicobiologic research into practice

Current Psychiatry Reviews

Volumn 4, Issue 2, 2008, Pages 73-79

  Dickerson, Bradford C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Magnetic resonance imaging; Mild cognitive impairment; Neuropsychology; Positron emission tomography

Indexed keywords

AMYLOID; APOLIPOPROTEIN E4; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; AMNESIA; BRAIN FUNCTION; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; NEUROBIOLOGY; NOMENCLATURE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM;

EID: 47749100141     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340008784529296     Document Type: Review

References (61)

1. Cummings JL, Doody R,Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007; 69: 1622-1634.
2. DeKosky ST,Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003; 302: 830-834.
3. Scheff SW, Price DA, Schmitt FA,Mufson EJ. Hippocampal synaptic loss in ea rly Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2005.
4. Gomez-Isla T, Price JL, McKeel DW, Jr., Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996; 16: 4491-4500.
5. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW,Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 2001; 58: 1395-1402.
6. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746.
7. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
8. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-246.
9. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-194.
10. Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63: 665-672.
11. Riley KP, Snowdon DA,Markesbery WR. Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol 2002; 51: 567-577.
12. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005; 64: 834-841.
13. Dickerson BC, Sperling RA, Hyman BT, Albert MS, Blacker D. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry 2007; 64: 1443-1450.
14. Storandt M, Grant EA, Miller JP,Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 2006; 67: 467-473.
15. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain 2007; 130: 2636-2645.
16. Renner JA, Burns JM, Hou CE, McKeel DW, Jr., Storandt M,Morris JC. Progressive posterior cortical dysfunction: a clinico-pathologic series. Neurology 2004; 63: 1175-1180.
17. Johnson JK, Head E, Kim R, Starr A, Cotman CW.Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999; 56: 1233-1239.
18. Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007; 68: 1205-1212.
19. Dickerson BC, Sperling RA. Neuroimaging Biomarkers for Clinical Trials of Disease-Modifying Therapies in Alzheimer's Disease. NeuroRx 2005; 2: 348-360.
20. Mueller SG, Weiner MW, Thal LJ, et al. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuro-imaging Initiative (ADNI). Alzheimer's and Dementia 2005; 1: 55-66.
21. Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get alzheimer's disease. Ann Neurol 2000; 47: 430-439.
22. Jack CR, Jr., Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999; 52: 1397-1403.
23. de Leon MJ, Golomb J, George AE, et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol 1993; 14: 897-906.
24. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging 2001; 22: 747-754.
25. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 2000; 57: 339-344.
26. Schott JM, Frost C, Whitwell JL, et al. Combining short interval MRI in Alzheimer's disease: Implications for therapeutic trials. J Neurol 2006; 253: 1147-1153.
27. Jack CR, Jr., Weigand SD, Shiung MM, et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 2007; (Epub ahead of print).
28. Schott JM, Fox NC, Frost C, et al. Assessing the onset of structural change in familial Alzheimer's disease. Arm Neurol 2003; 53: 181-188.
29. Jagust WJ, Zheng L, Harvey DJ, et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 2007; 63(1): 72-80.
30. Dickerson BC, Feczko E, Augustinack JC, et al. Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area. Neurobiol Aging 2007; (Epub ahead of print).
31. Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 2002; 99: 4703-4707.
32. Whitwell JL, Shiung MM, Przybelski SA, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2007.
33. Dickerson BC, Fenstermacher E, Salat DH, et al. Detection of cortical thickness correlates of cognitive performance: Reliability across MRI scan sessions, scanners, and field strengths. Neuroimage 2008; 39: 10-18.
34. Jack CR, Jr., Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002; 58: 750-757.
35. de Toledo-Morrell L, Dickerson B, Sullivan MP, Spanovic C, Wilson R,Bennett DA. Hemispheric differences in hippocampal volume predict verbal and spatial memory performance in patients with Alzheimer's disease. Hippocampus 2000; 10: 136-142.
36. Jack CR, Jr., Slomkowski M, Gracon S, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003; 60: 253-260.
37. Jagust WJ, Friedland RP, Budinger TF, Koss E,Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology 1988; 38: 909-912.
38. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multi-center FDG PET. Neuroimage 2002; 17: 302-316.
39. Chetelat G, Eustache F, Viader F, et al. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 2005; 11: 14-25.
40. Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005; 64: 1860-1867.
41. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42: 85-94.
42. Johnson KA, Jones K, Holman BL, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998; 50: 1563-1571.
43. Mega MS, Chu T, Mazziotta JC, et al. Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer's disease. Neuroreport 1999; 10: 2911-2917.
44. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709-7717.
45. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007; 69: 871-877.
46. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98: 3334-3339.
47. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752-758.
48. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset alzheimer's dementia. Proc Natl Acad Sci U S A 2004; 101: 284-289.
49. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319.
50. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355: 2652-2663.
51. Mintun MA, Larossa GN, Sheline YI, et al. [11C]CPIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-452.
52. Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci 1968; 7: 331-356.
53. Brys M, Pirraglia E, Rich K, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 2007; [epub ahead of print].
54. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234.
55. Buerger K, Zinkowski R, Teipel SJ, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002; 59: 1267-1272.
56. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 2007; 6: 295-303.
57. Chetelat G, Desgranges B, Landeau B, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 2008; 131: 60-71.
58. De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001; 22: 529-539.
59. Mosconi L, Sorbi S, de Leon MJ, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 2006; 47: 1778-1786.
60. de Leon MJ, DeSanti S, Zinkowski R, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006; 27: 394-401.
61. Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2007. [epub ahead of print].